Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: Synthesis, biological evaluation, and structure-activity relationships

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 2, 2009, Pages 305-308

  Horiuchi, Takao ^a   Chiba, Jun ^a   Uoto, Kouichi ^a   Soga, Tsunehiko ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Cyclin D1 CDK4 inhibitor; Thieno 2,3 d pyrimidin 4 yl hydrazone

Indexed keywords

2 PYRIDINECARBOXALDEHYDE [6 (TERT BUTYL)THIENO[2,3 D]PYRIMIDIN 4 YL]HYDRAZONE DERIVATIVE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; THIENO[2,3 D]PYRIMIDIN 4 YL HYDRAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CYTOTOXICITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE; TUMOR GROWTH;

CELL LINE, TUMOR; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDRAZONES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 57749118582     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.090     Document Type: Article

References (27)

1. Hunter T., and Pines J. Cell 79 (1994) 573
2. Sherr C. Science 274 (1996) 1672
3. Morgan D.O. Annu. Rev. Cell Dev. Biol. 13 (1997) 261
4. Pines J. Trends Biochem. Sci. 18 (1993) 195
5. Pines J. Nat. Cell Biol. 1 (1999) E73
6. Shapiro G.I. J. Clin. Oncol. 24 (2006) 1770
7. Khleif S.N., DeGregori J., Yee C.L., Otterson G.A., Kaye F.J., Nevins J.R., and Howley P.M. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 4350
8. Dyson N. Gene Dev. 12 (1998) 2245
9. Sandhu C., and Slingerland J. Cancer Detect. Prev. 24 (2000) 107
10. Bringold F., and Serrano M. Exp. Gerontol. 35 (2000) 317
11. Roussel M.F. Oncogene 18 (1999) 5311
12. Nevins J.R. Hum. Mol. Gen. 10 (2001) 699
13. Barnes D.M., and Gillett C.E. Breast Cancer Res. Treat. 52 (1998) 1
14. Grillo M., Bott M.J., Khandke N., McGinnis J.P., Miranda M., Meyyappan M., Rosfjord E.C., and Rabindran S.K. Breast Cancer Res. Treat. 95 (2006) 185
15. Malumbres M., and Barbacid M. Cancer Cell 9 (2006) 2
16. Buolamwini J.K. Curr. Pharm. Design 6 (2000) 379
17. Sanderowicz A.M. Cancer Biol. Ther. 2 (2003) S84
18. Hirai H., Kawanishi N., and Iwasawa Y. Curr. Top. Med. Chem. 5 (2005) 167
19. Fry D.W., Harvey P.J., Keller P.R., Elliott W.L., Meade M., Trachet E., Albassam M., Zheng X., Leopold W.R., Pryer N.K., and Toogood P.L. Mol. Cancer Ther. 3 (2004) 1427
20. VanderWel S.N., Harvey P.J., McNamara D.J., Repine J.T., Keller P.R., Quin III J., Booth R.J., Elliott W.L., Dobrusin E.M., Fry D.W., and Toogood P.L. J. Med. Chem. 48 (2005) 2371
21. Toogood P.L., Harvey P.J., Repine J.T., Sheehan D.J., VanderWel S.N., Zhou H., Keller P.P., McNamara D.J., Sherry D., Zhu T., Brodfuehrer J., Choi C., Barvian M.R., and Fry D.W. J. Med. Chem. 48 (2005) 2388
22. Tinney F.J., Cetenko W.A., Kerbleski J.J., Connor D.T., Sorenson R.J., and Herzig D.J. J. Med. Chem. 24 (1981) 878
23. Hozien Z.A., Atta F.M., Hassan Kh.M., Abdel-Wahab A.A., and Ahmed S.A. Synth. Commun. 26 (1996) 3733
24. Schinke E., Gewald K., and Böttcher H. Chem. Ber. 99 (1966) 94
25. Beam C.F., Sandifer R.M., Foote R.S., and Hauser C.R. Synth. Commun. 6 (1976) 5
26. Becton Dickinson FACS Calibur flow cytometer was used.
27. Solubilizing agent of CyDex Pharmaceuticals, Inc. was used.